Template Therapeutics (Template-Tx.ai) integrates generative AI, quantum simulation, and human tissue validation to accelerate drug discovery. Its platform designs and synthesizes novel small molecules optimized for potency, safety (ADMET), and pharmacokinetics, then validates them directly in engineered human tissues. The team demonstrated Pfizer-collaborated success with CardioGenAI and now targets autoimmune diseases via CXCR5-CXCL13 antagonists that disrupt B-cell IL-6 signaling or cancer. Using proteoform-level biomarkers and quantum ensemble optimization, Template-Tx.ai closes the AI-to-human validation loop—reducing risk, cost, and time to IND by aligning molecular design with human biology. A $100 K Blavatnik Award will fund validation of AI-generated lead compounds.